Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer

Area of Science:

• Oncology
• Genomics
• Epidemiology

Background:

• Early-stage breast cancer management requires continuous updates on risk stratification and treatment efficacy.
• Understanding molecular subtypes is crucial for personalized therapeutic strategies.
• Advancements in diagnostic tools and therapies necessitate regular reviews of current practices.

Purpose of the Study:

• To summarize recent advancements in the prevention and treatment of early-stage breast cancer.
• To highlight new epidemiological data on disease risk across different molecular subtypes.
• To review emerging therapeutic strategies and diagnostic biomarkers.

Main Methods:

• Review of recent epidemiological studies on breast cancer risk by molecular subtype.
• Analysis of long-term follow-up data from clinical trials (e.g., Aphinity study).
• Evaluation of neoadjuvant therapies and biomarker studies (e.g., residual cancer burden, Genomic Grade Index).

Main Results:

• New insights into individual disease risk based on molecular subtypes.
• Updated data on the efficacy of existing treatments and novel neoadjuvant therapies (e.g., atezolizumab for HER2-positive patients).
• Validation of biomarkers (e.g., residual cancer burden) for predicting treatment response.
• Investigation into multigene tests (e.g., Genomic Grade Index) to identify patients who can avoid chemotherapy.

Conclusions:

• Recent developments offer improved strategies for early-stage breast cancer prevention and treatment.
• Personalized medicine approaches, guided by molecular subtypes and biomarkers, are advancing.
• Genomic tests show promise in de-escalating treatment for select patient groups.